Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT04675294
Title Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors ALX Oncology Inc.
Age Groups: senior | adult
Covered Countries USA | ESP | CAN | BEL

Additional content available in CKB BOOST